Clinical Trials Logo

Sensory System Agents clinical trials

View clinical trials related to Sensory System Agents.

Filter by:
  • None
  • Page 1

NCT ID: NCT06462196 Not yet recruiting - Clinical trials for Major Depressive Disorder

Natural History of Depression, Bipolar Disorder and Suicide Risk

Start date: June 26, 2024
Phase:
Study type: Observational

Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medications will improve thoughts of suicide. People 18 years or older who are receiving treatment for depression, bipolar disorder, or suicide risk may take part in this study. Participants must have also been enrolled in protocol 01-M-0254. This study will be conducted at the NIH Clinical Center in Bethesda, MD. The study typically lasts up to 12 weeks, but may last longer if a participant s treatment continues past that time. Participants will have weekly interviews and questionnaires while they are being treated for their mood disorder. Other tests are optional and include psychological testing, blood draws, sleep tests, and imaging scans. These will be done at the start and the end of research participation....

NCT ID: NCT05615948 Completed - Clinical trials for Major Depressive Disorder

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression

Start date: December 6, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the effects of simultaneous administration of oral aspirin and oral ketamine as a therapeutic for those with Treatment Resistant Depression.

NCT ID: NCT04489420 Terminated - Clinical trials for Glioblastoma Multiforme

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

CYNK001GBM01
Start date: October 1, 2020
Phase: Phase 1
Study type: Interventional

This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy for the systemic cohort (IV) (intravenous). The intratumoral cohort (IT) will not be giving lymphodepletion. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating recurrent glioblastoma multiforme.

NCT ID: NCT04309084 Active, not recruiting - Clinical trials for Cardiovascular Diseases

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Start date: May 12, 2020
Phase: Phase 1
Study type: Interventional

This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT). The safety of this treatment will be evaluated, and researchers will want to learn if NK cells will help in treating Multiple Myeloma.